RxDoctor Payments Data

Caterina Oneto Araya, MD

Gastroenterology · New York, NYNPI 1245559764

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $461,251 of the $610,152 with a category attached, or 75.6%. 33 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 43.6% of the total. Reporting peaked in 2023 at $169,058 and has fallen 89.0% since, to $18,641 in 2025. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$610,152in general payments, 2019–2025

Across 1,416 payments — averaging $430.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$266K
  • AbbVie$120K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$89K
  • Ferring Pharmaceuticals Inc.$57K
  • Phathom Pharmaceuticals, Inc.$43K
  • Pfizer$15K
  • plus $20K from 27 others
$201,415in research payments, 2019–2025

Across 45 payments — averaging $4475.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$140K
  • E.r. Squibb & Sons, L.L.C.$31K
  • Bausch Health US, LLC$16K
  • Roche Products Limited$10K
  • Ferring Pharmaceuticals AS$5K

What the payments were for

  • Consulting fees$59,00010%
  • Speaking & faculty fees$461,25176%
  • Travel & lodging$52,8549%
  • Food & beverage$35,8736%
  • Education$1,1750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$610,152 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$30,577
Medicare patients
80
Services billed
290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine26$9,672
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates13$880
Omeprazole58$480
Pantoprazole Sodium21$234

Paid to pharmacies, not to this prescriber.

Other gastroenterology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →